Date: November 6, 2001
Location: Toronto, Canada
Symposium Web Page: www.multiplemyeloma.org/events/seminars.html
Sponsors: Multiple Myeloma Research Foundation and University of Toronto
Oct 22, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.
Oct 22, 2014
Dec 13, 2010